论文部分内容阅读
目的:观察美托洛尔和曲美他嗪对冠心病舒张功能不全患者左心室舒张功能以及血清炎症因子水平的影响。方法:筛选137例冠心病左室舒张功能不全患者,随机分成曲美他嗪组、美托洛尔组、联合组(曲美他嗪联合美托洛尔),分别在入选和治疗12个月后检测心绞痛症状、心脏超声、脑钠肽(BNP)、C-反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)。结果:联合组心绞痛治疗有效率(93.33%)较另2组高,但差异无统计学意义(P>0.05)。3组患者治疗后心室舒张功能均明显改善(P<0.01);BNP显著减少(P<0.01);炎症因子CRPI、L-6、TNF-α无明显改善(P>0.05)。结论:曲美他嗪和美托洛尔长期治疗后都能有效改善冠心病患者临床症状以及左室舒张功能;未发现2种药物对炎症因子有意义的影响。
Objective: To observe the effects of metoprolol and trimetazidine on left ventricular diastolic function and serum levels of inflammatory cytokines in patients with coronary heart disease with diastolic dysfunction. Methods: A total of 137 patients with left ventricular diastolic dysfunction in coronary heart disease were selected and randomly divided into trimetazidine group, metoprolol group and combination group (trimetazidine combined with metoprolol). The patients were enrolled and treated for 12 months Angina pectoris, echocardiography, BNP, CRP, IL-6 and TNF-α were detected. Results: The effective rate of angina pectoris group (93.33%) was higher than that of the other two groups, but the difference was not statistically significant (P> 0.05). The ventricular diastolic function was significantly improved in all three groups (P <0.01), BNP was significantly decreased (P <0.01), while the inflammatory factors CRPI, L-6 and TNF-α were not significantly improved (P> 0.05). CONCLUSION: Both trimetazidine and metoprolol can effectively improve clinical symptoms and left ventricular diastolic function after long-term treatment. No meaningful effect of the two drugs on inflammatory cytokines was found.